BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update Jul 30, 2019
BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia Jul 22, 2019
BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference Jun 18, 2019
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial Jun 10, 2019
BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs Jun 6, 2019
BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701 Jun 3, 2019
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases May 20, 2019
